Repositioning of mirodenafil, a clinically approved PDE5 inhibitor with good blood-brain barrier permeability, allows us to explore new avenues for an adequate polypharmacological AD therapeutic agent [15, 16]. Here, PDE5A is linked to Alzheimer disease.